Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Deoxypyridoxine is a synthetic analog of vitamin B6 (pyridoxine) and acts as a vitamin B6 antagonist. Its principal mechanism is inhibition of pyridoxal kinase, an enzyme critical in the regeneration and function of vitamin B6. This antagonism causes vitamin B6 deficiency, which suppresses immune function and produces metabolic derangements. As an immunosuppressant, deoxypyridoxine has demonstrated utility in animal models, such as reducing chronic granuloma formation and dampening cytokine production (TNF-α, IL-1, IL-6). Additionally, it inhibits sphingosine-1-phosphate lyase, proposed to increase the viability of pancreatic islet tissue by reducing apoptosis in transplantation contexts. It is considered toxic, especially during embryonic development, and is not used therapeutically in humans.[1][3][5][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deoxypyridoxine.